HeartSciences MyoVista High Sensitivity ECG Now Available in Europe

HeartSciences, a firm based outside of Dallas, Texas, is releasing in Europe its MyoVista high sensitivity electrocardiograph (hsECG) device that helps to screen patients for cardiac disease. It relies on a mathematical method known as continuous wavelet transform to process ECG data in a manner very different than conventional ECG. The company compares the way its MyoVista’s color representation of the heart gives a view of the heart’s distribution of energy to color Doppler radar giving a view into the energy distribution of a storm.

Early detection of cardiac conditions can significantly lower the later burden on patients as well as healthcare systems, and MyoVista claims some impressive capabilities. For example, according to HeartSciences, in a 200 patient trial looking for left ventricular diastolic dysfunction, the system “detected cardiac dysfunction in the resting (diastolic) phase of the cardiac cycle with 88 percent sensitivity and 87 percent specificity.” This was partially thanks to a machine learning algorithm that was used to process the data on top of MyoVista’s standard processing.

As far as clinical workflow goes, the twelve leads are applied as with a standard at rest protocol, so that part doesn’t change for the staff. Plus, the system can be used as a conventional ECG in conjunction with hsECG, or on its own.

“Currently, there’s a significant diagnostic gap in detecting heart disease early, resulting in a burden on both patients and healthcare systems,” said Andrew Simpson, chairman, HeartSciences. “We believe MyoVista hsECG could play an important role in achieving the preventative treatment ambitions of many healthcare systems as well as help reduce unnecessary healthcare expenditures.”